Thomas J. Galloway, MD

Thomas Galloway, MD

Clinical Locations

Primary Location

Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111


Assistant Professor, Department of Radiation Oncology

Chief, Division of Head and Neck Radiation Oncology

Medical Director, Clinical Research

TRDG Member, Head and Neck CancerMelanoma and Skin CancerThyroid and Endocrine Cancer

Treatment Focus

  • Intensity modulated radiation therapy
  • Stereotactic body radiation therapy
  • Modulated electron beam therapy
  • Interstitial brachytherapy
  • Rotational arc therapy

Research Program

Key Awards

  • ARRO Educator of the year, Fox Chase Cancer Center 2013
  • Practical Radiation Oncology, Certificate in Excellence of Reviewing, 2013

    Treatment Philosophy

    I joined Fox Chase after completing my residency at the University of Florida in 2010. I specialize in treating cancers of the head and neck and skin cancer.

    Cancer is a complicated, confusing diagnosis. Cancers of the head and neck are particularly challenging because they occur in areas that can affect our ability to perform some of our most basic functions: breathing, speaking, and eating.

    I came to Fox Chase because I believe that the best way to cure these difficult cancers while maintaining quality of life is through a multi-disciplinary approach. Some cancers are cured with radiation alone, some need the assistance of both surgery and chemotherapy, and some are cured without radiation. The team approach at Fox Chase ensures that many different disciplines are working together to decide the best treatment for your unique case with one unifying goal: curing your cancer while avoiding unnecessary toxicity

    Education, Training & Credentials

    Educational Background

    • MD, University of Florida, Gainesville, FL, 2005
    • BS, Chemistry, University of Florida, Gainesville, FL, 2001


    • American Board of Radiology
    • Radiation Oncology


    • American Society of Therapeutic Radiology (ASTRO)
    • Radiation Therapy Oncology Group (RTOG)
    • Institutional Principal Investigator for Fox Chase Cancer Center (Institution 2212) July 2013 - Present
    • American Radium Society (ARS)
    • Radiological Society of North America (RSNA)
    • American College of Radiology (ACR)
    • Eastern Cooperative Oncology Group (ECOG)

      Honors & Awards

      • ARRO Educator of the year, Fox Chase Cancer Center 2013
      • Practical Radiation Oncology, Certificate in Excellence of Reviewing, 2013
      Patient Stories

      Tierra Ryan


      Tierra Ryan


      At 31, Tierra Ryan was a typical young professional woman. A pharmacist and a medical writer for a large pharmaceutical company, Tierra was in good health, worked out regularly, and did her best to maintain a healthy lifestyle. In early spring, 2014, Tierra began to notice changes in her body as she was unusually tired and had profound night sweats.

      Stephen Meier

      Head & Neck Cancer

      Stephen Meier

      Head & Neck Cancer

      Stephen Meier is proud of his Philadelphia roots. This Somerton resident speaks with a decidedly Philly cadence, an especially notable feature since he had his larynx removed in 2012 when he was 59.

      Paul Reitano

      Head & Neck Cancer

      Paul Reitano

      Head & Neck Cancer

      Paul Reitano was in very good health prior to his cancer diagnosis in 2012. An avid participant of martial arts and working-out, he is fortunate to have two successful careers: his day job is working as an engineer’s assistant for the Delaware Valley Regional Planning Commission, and his second career is as a photographer of both of corporate and social events. But his world turned upside down in October, 2012, when Paul felt a lump in the left side of his neck.

      Richard Millham

      Skin Cancer

      Richard Millham

      Skin Cancer

      When he started running in 1989 at the age of 55, Dick Millham thought he was taking strides towards a healthier lifestyle. And while he was indeed doing his heart and body good, the fact that he ran in the heat of summer without the benefit of hat, shirt or sunscreen eventually caught up with him. “I always thought that my olive skin meant I wouldn’t have a problem with the sun or skin cancer,” says Dick.

      B. Mark Wilson

      Head & Neck Cancer

      B. Mark Wilson

      Head & Neck Cancer

      On May 6, 2014, B. Mark Wilson of Smyrna, Delaware, made a chance visit to Fox Chase Cancer Center. The 51-year-old came to accompany his father, George, for a follow-up visit. The elder Wilson had been treated for kidney cancer two years earlier. Mark, who had just been diagnosed with stage IV throat cancer, was just days away from his own surgery, and brought along his medical paperwork. “I was hoping for a second opinion,” he admitted. “Little did I know Fox Chase has a Rapid Access Program, which meant I could be seen immediately.

      Research Profile

      Research Program

      Research Interests

      • Head and neck cancer
      • Head and neck cancer survivorship
      • Skin Cancer (both melanoma and non-melanoma)
      • Merkel Cell Carcinoma Radiation target delineation
      • Pre-treatment imaging evaluation beyond the diagnosis
      • Impact of time to treatment in the curative management of head and neck cancer

      Selected Publications

      Murphy CT, Galloway TJ, Handorf EA, Wang L, Mehra R, Flieder D, Ridge JA. The Survival Impact of Increasing Time to Treatment Initiation for Patients with Head and Neck Cancer in the United States. Accepted for publication in Journal of Clinical Oncology PubMed

      Murphy CT, Devarajan K, Wang LS, Mehra R, Ridge JA, Fundakowski C, Galloway TJ. Pre-Treatment Tumor-Specific Growth Rate as a Temporal Biomarker that Predicts Treatment Failure and Improves Risk Stratification for Oropharyngeal Cancer. Accepted for publication in Oral Oncology PubMed

      Lango MN, Galloway TJ, Mehra R, Ebersole B, Liu JC, Burtness B, Moran K, Ridge JA.  Impact of baseline dysphagia on acute feeding tube placement in head and neck cancer patients undergoing definitive radiation.  Epub ahead of print in Head and Neck PubMed

      Galloway TJ, Ridge JA.  Management of squamous cancer metastatic to cervical nodes with unknown primary.  Epub ahead of print in Journal of Clinical Oncology PubMed

      Galloway TJ, Wirth L, Colevas D, Gilbert J, Bauman J, Saba N, Raben D, Mehra R, Burtness B, Jimeno A. A Phase 1 Study of CUDC-101, a multitarget inhibitor of HDACs, EGFR and HER2, in combination with chemoradiation in patients with head and neck squamous cell carcinoma (Clinical Cancer Research 2015; 21(7) 1566-1573). PubMed

      Murphy CT, Galloway TJ, Handorf EA, Wang L, Mehra R, Flieder D, Ridge JA. Increasing time to treatment initiation for squamous cell carcinoma of the head and neck: An analysis of the National Cancer Database. (Cancer 2015; 121(8) 1204-1213). PubMed

      Nguyen-Tan PF, Zhang QE, Ang KK, Wheeler RH, Weber RS, Rosenthal DI, Bahary JP, Kim H, Silverman C, Raben A, Galloway T, Vigneault E, Gore E, Westra WH, Chung CH, Jordan RC, Gillison ML, List M, Le QT. A Randomized Phase III Trial to Test Accelerated versus Standard Fractionation in Combination with Concurrent Cisplatin for Head and Neck Carcinomas (RTOG 0129): Long Term Report of Efficacy and Toxicity. (Journal of Clinical Oncology 2014; 32(34) 3858-3867 

      Lango MN, Egleston B, Fang CY, Burtness B, Galloway T, Liu JC, Mehra R, Ebersole B, Moran KM, Ridge JA. Baseline Health Perceptions, weight-loss and survival in head and neck cancer. (Cancer 2014; 120(6):840-7

      Keller L, Galloway TJ, Holdbrook T, Ruth K, Yang D, Dubyk C, Flieder D, Lango M, Burtness B, Mehra M, Ridge JA. p16 Status, Pathologic and Clinical Characteristics, Biomolecular Signature, and Long Term Outcomes in Unknown Primary Carcinomas of the Head and Neck.  (Head and Neck 2014 36(12) 1677-1684

      Sopka DM, Li T, Lango MN, Mehra R, Liu JC, Burtness B, Flieder D, Ridge JA, Galloway TJ. Dysplasia at the Margin? Investigating the case for Subsequent Therapy in Squamous Cell Carcinoma of the Oral Tongue. (Oral Oncology 2013 49(11): 1083-1087)

      Burtness B, Bauman J, Galloway T. Novel Targets in HPV-Negative Head and Neck Cancer – Overcoming Resistance to EGFR Inhibition. (Lancet Oncology 2013; 14(8): e302-9).

      Lango M, Flieder D, Arrangoiz R, Yu M, Li T, Burtness B, Mehra R, Galloway T, Veloski C, Ridge JA. Effect of extranodal extension on biochemical endpoints, nodal persistence and systemic disease progression in metastatic papillary thyroid carcinoma. (Thyroid. 2013; 23(9): 1099-1105)

      Galloway TJ, Lango MN, Burtness B, Mehra R, Ruth K, Ridge JA. Unilateral Neck Therapy in the Human Papillomavirus Era: Accepted Regional Spread Patterns. (Head and Neck. 2013; 35(2): 160-164)

      Galloway TJ, Amdur RJ, Liu C, Yeung A, Mendenhall WM. Revisiting Unnecessary Larynx Irradiation with Whole Neck IMRT. (Practical Radiation Oncology. 2011 1, 27-32)

      Galloway TJ, Morris CG, Mancuso AA, Amdur RJ, Mendenhall WM. Impact of Radiographic Findings on Prognosis for Skin Cancer with Clinical Perineural Invasion. Cancer. 2005 Mar 15; 103(6):1254-7 PubMed

      Additional Publications

      My NCBI